15.10
薬理動態モデル:Emax 薬剤濃度効果モデル
View the full transcript and gain access to JoVE Core videos
Q1: What happens when a drug binds to a receptor?
When a drug binds to a receptor, it forms a drug-receptor complex that triggers a pharmacodynamic response. This reversible interaction is governed by association and dissociation rates, with the magnitude of the drug's effect proportional to the concentration of the drug-receptor complex formed at equilibrium.
Q2: How does the Hill coefficient affect the dose-response curve?
The Hill coefficient defines the steepness of the effect-concentration curve. Values above five create steep curves where missed doses significantly reduce therapeutic effects, while values less than one yield broader slopes with more gradual responses, directly influencing the intensity of dose-effect relationship.
Q3: What is the difference between KD and EC50 in the Emax model?
KD is the dissociation constant describing drug-receptor binding affinity at equilibrium. EC50 is the drug concentration producing half-maximal effect. The Emax equation uses EC50 instead of KD to directly relate plasma drug concentration to observed pharmacodynamic response and therapeutic outcomes.
Q4: Why is receptor occupancy theory important for the Emax model?
Receptor occupancy theory forms the foundation of the Emax model, positing that drug effect is directly proportional to the number of occupied receptors. This principle justifies the assumption that effect magnitude correlates with drug-receptor complex concentration, enabling quantitative prediction of dose-response relationships.
Q5: What factors determine drug-receptor complex formation at equilibrium?
At equilibrium, drug-receptor complex formation is determined by association constant (kon), dissociation constant (koff), maximum receptor density (RT), and drug concentration (C). The rate of complex formation equals the rate of dissociation, establishing a stable relationship described by the dissociation constant KD.
Q6: How does the Emax model predict drug effects across different concentrations?
The Emax model generates a curvilinear effect-versus-plasma-concentration plot, predicting how pharmacodynamic response changes with drug concentration. This nonlinear relationship reflects receptor saturation kinetics, allowing clinicians to anticipate therapeutic effects and optimize dosing regimens based on exposure, response and effect across patient populations.
Q7: Why is the Emax model central to drug discovery and development?
The Emax model quantifies the relationship between drug concentration and pharmacodynamic response, guiding dosing regimens and therapeutic strategies. By incorporating receptor occupancy theory and Hill coefficient considerations, it enables researchers to predict clinical outcomes and optimize drug development decisions for regulatory approval.